Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Gastroesophageal Reflux Disease Therapeutics Market, by Type
1.4.2 Europe Gastroesophageal Reflux Disease Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Gastroesophageal Reflux Disease Therapeutics Market by Type
3.1 Europe Antacids Market by Country
3.2 Europe Proton Pump Inhibitors (PPIs) Market by Country
3.3 Europe H2 Receptor Blockers Market by Country
3.4 Europe Pro-kinetic Agents Market by Country
Chapter 4. Europe Gastroesophageal Reflux Disease Therapeutics Market by Country
4.1 Germany Gastroesophageal Reflux Disease Therapeutics Market
4.1.1 Germany Gastroesophageal Reflux Disease Therapeutics Market by Type
4.2 UK Gastroesophageal Reflux Disease Therapeutics Market
4.2.1 UK Gastroesophageal Reflux Disease Therapeutics Market by Type
4.3 France Gastroesophageal Reflux Disease Therapeutics Market
4.3.1 France Gastroesophageal Reflux Disease Therapeutics Market by Type
4.4 Russia Gastroesophageal Reflux Disease Therapeutics Market
4.4.1 Russia Gastroesophageal Reflux Disease Therapeutics Market by Type
4.5 Spain Gastroesophageal Reflux Disease Therapeutics Market
4.5.1 Spain Gastroesophageal Reflux Disease Therapeutics Market by Type
4.6 Italy Gastroesophageal Reflux Disease Therapeutics Market
4.6.1 Italy Gastroesophageal Reflux Disease Therapeutics Market by Type
4.7 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market
4.7.1 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market by Type
Chapter 5. Company Profiles
5.1 Takeda Pharmaceutical Company Limited
5.1.1 Company Overview
5.1.2 Financial Analysis
5.1.3 Regional Analysis
5.1.4 Research & Development Expense
5.2 AstraZeneca PLC
5.2.1 Company Overview
5.2.2 Financial Analysis
5.2.3 Regional Analysis
5.2.4 Research & Development Expenses
5.3 GlaxoSmithKline PLC (GSK)
5.3.1 Company Overview
5.3.2 Financial Analysis
5.3.3 Segmental and Regional Analysis
5.3.4 Research & Development Expense
5.4 Johnson & Johnson
5.4.1 Company Overview
5.4.2 Financial Analysis
5.4.3 Segmental &Regional Analysis
5.4.4 Research & Development Expenses
5.5 Ironwood Pharmaceuticals, Inc.
5.5.1 Company Overview
5.5.2 Financial Analysis
5.5.3 Regional Analysis
5.5.4 Research & Development Expenses
5.6 Eisai Co., Ltd.
5.6.1 Company Overview
5.6.2 Financial Analysis
5.6.3 Segmental and Regional Analysis
5.6.4 Research & Development Expenses
5.7 Medigus Ltd.
5.7.1 Company Overview
5.7.2 Financial Analysis
5.7.3 Segmental and Regional Analysis
5.7.4 Research & Development Expenses
5.8 Sebela Pharmaceuticals
5.8.1 Company Overview
5.8.2 Recent strategies and developments:
5.8.2.1 Partnerships, Collaborations, and Agreements:
5.9 Phathom Pharmaceuticals, Inc.
5.9.1 Company Overview
5.9.2 Research & Development Expenses
5.9.3 Recent strategies and developments:
5.9.3.1 Partnerships, Collaborations, and Agreements:
5.10. Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
5.10.1 Company Overview
5.10.2 Recent strategies and developments:
5.10.2.1 Product Launches and Product Expansions:
Unique Offerings 
